Temple therapeutics, a leading enterprise in the field of women's health invested by Everpower international, officially launched its listing in Hong Kong, and is currently conducting a Pre-IPO Financing.

Temple was started in 2015. It is a new international professional pharmaceutical company integrating innovation, precision targeted therapy, value-added technology and portfolio platform. Different from the traditional biotechnology companies, Temple is far away from the high-density competition area and pays attention to the neglected public and female health problems. It uses the company's insight in the professional field and the world-class leading expert team to provide unsatisfied market demand from multiple perspectives.

The company mainly focuses on the pipeline development of three plates: postoperative tissue adhesion, diagnosis and treatment of ectopic uterine mucosa and gynecologic cancer.